• 2 August, 2017
  • A study on the first use of CRISPR technology in the U.S. to correct a disease-causing genetic defect in early stage human embryos.
    Full story
  • 6 May, 2017
  • 5/6/2017 4:00:00 AM

    The ISSCR wrote to members of the Texas House of Representatives, U.S., to oppose House Bill 661, House Bill 810, and House Bill 3236, which would allow investigational agents to be sold to patients without first providing rigorous evidence of safety and efficacy. The ISSCR believes the legislation would put patients at serious risk of harm from unproven treatments.
    Full story
  • 17 March, 2017
  • The FY2018 Discretionary Budget Plan put forward by the U.S. Administration includes dramatic cuts in funding for science and research programs that would threaten biomedical research and its translation into new therapies for millions of people worldwide.
    Full story
  • The ISSCR Opposes U.S. Administration Executive Order on Immigration

  • 30 January, 2017
  • 1/30/2017 6:00:00 AM

    The ISSCR issued a statement opposing a U.S. executive order on immigration.
    Full story
  • The ISSCR Announces 2017 Award Recipients: McEwen Award for Innovation, ISSCR Dr. Susan Lim Outstanding Young Investigator Award, ISSCR Tobias Award Lecture, and ISSCR Public Service Award

  • 23 January, 2017
  • 1/23/2017 6:00:00 AM

    The ISSCR awards recognize outstanding scientists in the field of stem cell research and regenerative medicine. Award recipients are selected by their peers, and receive the honor at the ISSCR annual meeting, where they are invited to present their science.
    Full story
  • ISSCR Comments on 21st Century Cures Act in U.S.

  • 9 December, 2016
  • The ISSCR supports the increase in biomedical research funding in the 21st Century Cures Act in the U.S. It also underscores concern that the bill's streamlined process for FDA review and approval of regenerative therapies include a rigorous review of scientific and clinical evidence to ensure safety and efficacy.
    Full story
  • ISSCR Comments to Australian Therapeutic Goods Administration on Regulation of Autologous Cell and Tissue Products

  • 1 November, 2016
  • In comments to the Australian Therapeutic Goods Administration (TGA), the ISSCR supported regulation of autologous products that involve more than minimal manipulation of a patient’s cells and place strict limitations on the direct advertisement of cell-based therapies. The comments were in response to the TGA's call for input from interested parties about the regulation of autologous cell and tissue products.
    Full story
  • European Society of Gene and Cell Therapy & ISSCR to Present Latest in Stem Cell Research, Gene Editing and Gene Therapy 18-21 Oct., Florence IT - 30 Sept., 2016

  • 30 September, 2016
  • The European Society of Gene and Cell Therapy (ESGCT) & ISSCR host an International Symposium to Present the Latest in Stem Cell Research, Gene Editing and Gene Therapy. Latest news and developments in research will be part of the scientific programming.
    Full story
  • ISSCR Opposes the REGROW Act

  • 15 September, 2016
  • The ISSCR opposes the REGROW Act, which would allow certain cell and tissue-based therapeutics to be marketed without first providing rigorous evidence of safety and efficacy. If passed, this legislation could negatively impact the development of stem cell therapies, the integrity of the emerging regenerative medicine market, and the health and safety of people using stem cell products approved under this Act.
    Full story
  • ISSCR Comments Before FDA Panel on Draft Guidances Relating to the Regulation of Human Cells, Tissues, or Cellular or Tissue-Based Products

  • 13 September, 2016
  • The ISSCR today underscored the need for careful oversight and regulation of stem cell research at every stage in the process of developing therapeutic products for patient use.
    Full story
  • ISSCR Comments Regarding Proposed Changes to the U.S. National Institutes of Health Guidelines on Human Stem Cell Research

  • 7 September, 2016
  • The ISSCR supports the continued assessment of the U.S. National Institutes of Health (NIH) Guidelines for Human Stem Cell Research. We applaud the proposed end to the current moratorium on U.S. federal funding of human-animal chimera research involving the introduction of human pluripotent cells into early stage animal embryos.
    Full story
  • ISSCR Congratulates George Q. Daley on Being Named Dean of Harvard Medical School

  • 10 August, 2016
  • ISSCR Congratulates George Q. Daley, ISSCR past president, for being named dean of Harvard Medical School. August, 2016.
    Full story
  • ISSCR Favors NIH Proposal on Human-Animal Chimera Research

  • 8 August, 2016
  • The ISSCR is pleased that the U.S. National Institutes of Health (NIH) is considering an end to the moratorium on NIH funding of human-animal chimera research (NIH Notice, 8-4-16).
    Full story
  • ISSCR Submits Comments to NAS Regarding Human Gene Editing

  • 7 July, 2016
  • The ISSCR provided comments to the National Academy of Science/National Academy of Medicine Committee on Human Gene Editing regarding scientific, medical, and ethical considerations.
    Full story
  • The ISSCR Announces Los Angeles as Site of 2019 Annual Meeting

  • 13 June, 2016
  • 6/13/2016 5:00:00 AM

    The ISSCR Announces Los Angeles, CA as the site of its 2019 annual meeting, noting that it's the first time the organization will be meeting in that city. ISSCR 2019 is expected to draw more than 3,000 stem cell researchers and professionals from around the globe to the Los Angeles Convention Center 26-29 June, 2019.
    Full story
  • ISSCR Releases Updated Guidelines for Stem Cell Research and Clinical Translation

  • 12 May, 2016
  • The ISSCR, the world’s largest professional organization of stem cell scientists, today released newly updated guidelines for stem cell research and the development of new clinical therapies. Guidance addresses key scientific, ethical, social, and policy challenges raised by new technologies and emerging areas of stem cell discovery and application.
    Full story
  • ISSCR announces RFP for European co-sponsorship of the 2021 annual meeting

  • 2 March, 2016
  • The ISSCR announces an RFP for co-sponsorship of the 2021 annual meeting
    Full story
  • ISSCR Endorses Fetal Tissue Research as Essential

  • 26 February, 2016
  • The International Society for Stem Cell Research (ISSCR) is the world’s leading professional organization of stem cell scientists, representing more than 4,000 members in 45 U.S. states and 65 countries around the world. The ISSCR is opposed to recent efforts to inappropriately limit or prohibit biomedical research using fetal tissue. These proposals, if enacted, would obstruct critical biomedical research and inhibit efforts to improve human health. If enacted in the past, such limits would have delayed or prevented the development of therapies that have saved millions of lives.
    Full story
  • The International Society for Stem Cell Research Announces the 2016 Recipients of the McEwen Award for Innovation, the ISSCR Dr. Susan Lim Outstanding Young Investigator Award and the inaugural ISSCR Tobias Award Lecture

  • 10 February, 2016
  • 2/10/2016 5:00:00 AM

    The International Society for Stem Cell Research (ISSCR) is excited to announce the society’s 2016 award recipients, who will be formally recognized at its annual meeting, taking place 22-25 June, 2016 in San Francisco, California, U.S.
    Full story
    View All ISSCR News